103 related articles for article (PubMed ID: 29776250)
1. Towards a framework for personalized healthcare: lessons learned from the field of rare diseases.
Tambuyzer E
Per Med; 2010 Sep; 7(5):569-586. PubMed ID: 29776250
[TBL] [Abstract][Full Text] [Related]
2. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
3. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
4. Developing a patient-directed policy framework for managing orphan and ultra-orphan drugs throughout their lifecycle.
Menon D; Stafinski T; Dunn A; Wong-Rieger D
Patient; 2015 Feb; 8(1):103-17. PubMed ID: 25559762
[TBL] [Abstract][Full Text] [Related]
5. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
Herder M
Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
[TBL] [Abstract][Full Text] [Related]
6. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
[TBL] [Abstract][Full Text] [Related]
7. Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada.
Gibson S; von Tigerstrom B
J Law Biosci; 2015 Jul; 2(2):263-291. PubMed ID: 27774196
[TBL] [Abstract][Full Text] [Related]
8. Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases - Is It Time to Update the EU's Orphan Regulation? And if so, What Should be Changed?
Horgan D; Moss B; Boccia S; Genuardi M; Gajewski M; Capurso G; Fenaux P; Gulbis B; Pellegrini M; Mañú Pereira MDM; Gutiérrez Valle V; Gutiérrez Ibarluzea I; Kent A; Cattaneo I; Jagielska B; Belina I; Tumiene B; Ward A; Papaluca M
Biomed Hub; 2020; 5(2):1-11. PubMed ID: 33564657
[TBL] [Abstract][Full Text] [Related]
9. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.
Arai H; Ouchi Y; Toba K; Endo T; Shimokado K; Tsubota K; Matsuo S; Mori H; Yumura W; Yokode M; Rakugi H; Ohshima S
Geriatr Gerontol Int; 2015 Jun; 15(6):673-87. PubMed ID: 25656311
[TBL] [Abstract][Full Text] [Related]
10. The re-emerging concept of personalized healthcare.
Xu LH; Zheng H; Sedmak DD; Sadée W
Per Med; 2008 Sep; 5(5):457-469. PubMed ID: 29783441
[TBL] [Abstract][Full Text] [Related]
11. Rethinking Giftedness and Gifted Education: A Proposed Direction Forward Based on Psychological Science.
Subotnik RF; Olszewski-Kubilius P; Worrell FC
Psychol Sci Public Interest; 2011 Jan; 12(1):3-54. PubMed ID: 26168418
[TBL] [Abstract][Full Text] [Related]
12. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
13. Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes DA; Tunnage B; Yeo ST
QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
[TBL] [Abstract][Full Text] [Related]
14. Family pediatrics: report of the Task Force on the Family.
Schor EL;
Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
[TBL] [Abstract][Full Text] [Related]
15. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
16. The revitalization of U.S. dental education.
DePaola DP
J Dent Educ; 2008 Feb; 72(2 Suppl):28-42. PubMed ID: 18250375
[TBL] [Abstract][Full Text] [Related]
17. The road to success. Long-term prognosis for persons living with HIV in Denmark - time trends and risk factors.
Lohse N
Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836803
[TBL] [Abstract][Full Text] [Related]
18. Creating a European Union framework for actions in the field of rare diseases.
Moliner AM
Adv Exp Med Biol; 2010; 686():457-73. PubMed ID: 20824460
[TBL] [Abstract][Full Text] [Related]
19. [A proposal for reforming psychologists' training in France and in the European Union].
Bouchard JP
Encephale; 2009 Feb; 35(1):18-24. PubMed ID: 19250989
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
